USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
1 . A method for treating a metabolic disorder or for increasing satiety in a subject in need thereof, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject.
2 . The method of claim 1 , wherein said metabolic disorder is obesity.
3 . The method of claim 1 , wherein said metabolic disorder is selected from the group comprising metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus (such as, for example, Type 2 Diabetes), glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnoea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer.
4 . A method for increasing energy expenditure of a subject, optionally without impacting the food intake of said subject, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject.
5 . (canceled)
6 . The method of claim 1 , wherein viable cells of Akkermansia muciniphila are administered to the subject in need thereof.
7 . The method of claim 1 , wherein Akkermansia muciniphila is orally administered.
8 . The method of claim 1 , wherein an amount of Akkermansia muciniphila is ranging from about 1.10 4 to about 1.10 12 cfu, from about 1.10 5 to about 1.10 11 cfu, or from about 1.10 6 to about 1.10 10 cfu is administered to the subject.
9 . The method of claim 1 , wherein the Akkermansia muciniphila is administered at least three times a week.
10 . The method of claim 1 , wherein the Akkermansia muciniphila is co-administered with another probiotic strain and/or with one or more prebiotics.
11 . The method of claim 1 , wherein the Akkermansia muciniphila is administered as a composition in association with an excipient.
12 . The method of claim 11 , wherein said composition is a nutritional composition.
13 . The method of claim 11 , wherein said composition is orally administered.
14 . The method of claim 1 , wherein the Akkermansia muciniphila is administered as a pharmaceutical composition in association with a pharmaceutically acceptable vehicle.
15 . (canceled)
16 . A method for promoting weight loss in a subject in need thereof, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject.
17 . (canceled)